Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...

The market expects Regeneron (REGN) to deliver a year-over-year decline in earnings on lower revenues when it reports results ...

S&P 500 EPS growth is expected to come in at 4.8% for Q2, which would be the lowest growth rate since Q4 2023.

Our Top 5 Analyst Questions Regeneron’s Q1 Earnings Call ・Tyler Van Buren (TD Cowen) asked about the timeline and specifics behind the EYLEA HD pre-filled syringe regulatory delay. CEO Leonard ...